Factor XI (plasma thromboplastin anteced- Factor XI deficiency was first reported as a hemophilia-like syndrome by Rosenthal and coworkers in 1953 (1). This deficiency differs from classic hemophilia, however, in that the bleeding tendency is usually mild or absent, and either sex can be affected (for reviews, see refs. 2 and 3). Generally, spontaneous bleeding, such as hemarthrosis and purpura, is rare, and hemorrhage most often occurs only after trauma or minor surgery, such as circumcision, tonsillectomy, or dental extraction. Factor XI deficiency is rather unusual, however, in that an extreme variation in bleeding manifestations exists, ranging from a complete lack of symptoms to hemorrhage requiring multiple blood transfusions. Factor XI deficiency is inherited as an autosomal recessive trait (4) in which bleeding may occur in homozygotes and, perhaps, in heterozygotes (5). Factor XI deficiency is typically characterized by the virtual absence of factor XI coagulant activity as well as a lack of cross-reacting material in the circulating plasma (6). Thus far, a major portion of the factor XI-deficient patients have been found in the Ashkenazi Jewish population. In Israel, homozygotes occur at a frequency of about 1 in 190, whereas the heterozygote frequency is about 1 in 8 (7). Accordingly, factor XI deficiency is one of the most frequent genetic disorders in this ethnic group. Factor XI deficiency has also been described in patients of other ethnic backgrounds, but these occurrences are less common (6, 8) .
Factor XI deficiency was first reported as a hemophilia-like syndrome by Rosenthal and coworkers in 1953 (1) . This deficiency differs from classic hemophilia, however, in that the bleeding tendency is usually mild or absent, and either sex can be affected (for reviews, see refs. 2 and 3). Generally, spontaneous bleeding, such as hemarthrosis and purpura, is rare, and hemorrhage most often occurs only after trauma or minor surgery, such as circumcision, tonsillectomy, or dental extraction. Factor XI deficiency is rather unusual, however, in that an extreme variation in bleeding manifestations exists, ranging from a complete lack of symptoms to hemorrhage requiring multiple blood transfusions. Factor XI deficiency is inherited as an autosomal recessive trait (4) in which bleeding may occur in homozygotes and, perhaps, in heterozygotes (5) . Factor XI deficiency is typically characterized by the virtual absence of factor XI coagulant activity as well as a lack of cross-reacting material in the circulating plasma (6) . Thus far, a major portion of the factor XI-deficient patients have been found in the Ashkenazi Jewish population. In Israel, homozygotes occur at a frequency of about 1 in 190, whereas the heterozygote frequency is about 1 in 8 (7) . Accordingly, factor XI deficiency is one of the most frequent genetic disorders in this ethnic group. Factor XI deficiency has also been described in patients of other ethnic backgrounds, but these occurrences are less common (6, 8) .
The recent characterization of the normal factor XI gene in our laboratory (9) has made it possible to study the genetic abnormalities in six patients from the Ashkenazi population. In this report, three different mutations present in these patients are identified.
MATERIALS AND METHODS
Construction of Genomic Libraries, Cloning, and DNA Sequencing. High molecular weight DNA was isolated from peripheral lymphocytes (50 ml of whole blood) of six patients designated as Cleveland 1-6 (CL1-CL6). DNA from CL3 was digested with EcoRI restriction enzyme followed by fractionation on a 5-25% (wt/vol) NaCl gradient (10) . The 18-kb DNA fraction was then pooled, ligated into a A Dash vector (Stratagene), and packaged with Gigapack Gold (Stratagene) in vitro. Seven recombinant phage (CL3-1 to CL3-7) were isolated by plaque hybridization using a radiolabeled factor XI cDNA probe (9) . Five genomic DNA fragments generated by EcoRI and HindIll digestion of three phage clones (CL3-1, CL3-2, and CL3-6) were subcloned into pTZ vectors. Single-stranded DNA from pTZ was prepared from the medium of pTZ-transformed Escherichia coli cells superinfected with M13K07 helper phage. All the exons and exon-intron boundaries were sequenced by the dideoxy chain-termination method (11) with synthetic oligonucleotides as primers.
Alternative Strategy for Rapid Identification of Mutations. Thirteen pairs of oligonucleotide primers were used to amplify all the exons and intron/exon boundaries of the factor XI gene by the polymerase chain reaction (PCR) for DNA sequence analyses. These primers were changed slightly from an exact complementary DNA sequence with the gene to produce convenient restriction sites for cloning and sequencing. Each of the 12 independent exons and their intron/ exon boundaries were amplified except exons 8, 9, and 10, which were amplified as a single segment of 711 base pairs (bp). Five or more M13 phage clones derived from each amplified fragment were sequenced to improve the likelihood that both alleles in CL4 were being examined.
Analysis of the Mutant Allele. 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. A detailed analysis was made of the defective factor XI genes in one patient (CL3) by DNA sequence analysis. The abnormal factor XI genes present in two adjacent EcoRI fragments of 18 kilobases (kb) in length (Fig. 1A) were cloned into the vector A DASH (Stratagene), and seven genomic clones were isolated (CL3-1 to CL3-7). One clone (CL3-1) covered the 5' half of the gene, and the six remaining clones (CL3-2 to CL3-7) covered the 3' half of the gene, as shown by restriction mapping.
The sequences of all 15 exons, their adjacent intron junctions, as well as the 5'-and 3'-flanking regions of the gene were then determined in clones CL3-1 and CL3-2 by the dideoxy chain-termination method (11) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] in the normal factor XI gene (9) thetic oligonucleotide primers. These analyses showed that the defective factor XI gene was identical in DNA sequence to the normal gene in the regions examined, except for a single base substitution at the splice junction boundary of the last intron (intron N). This mutation interrupts the coding region of the mRNA between amino acids Lys-185 and Gly-186just before the active-site, Ser-188, in the light chain. In this boundary, the G in the obligatory 5'-splice donor dinucleotide GT (12) was changed to an A (Fig. 1B) . This splice junction mutation (designated type-I mutation) could give rise to the following abnormally processed mRNAs. (i) The entire intron N might be unspliced and retained in the mRNA. Translation of this mRNA would extend the polypeptide 5 residues beyond exon 14 to a stop codon located within intron N (9). This change would result in a truncated polypeptide of 559-amino acid residues that lacks an activesite serine. (ii) Cryptic splice sites could be used, as has been shown in e30 thalassemia (13, 14) , and would lead to premature termination of translation. (iii) Exon 14 may be omitted, resulting in the splicing of exon 13 directly to exon 15 analogous to a defective gene for phenylalanine hydroxylase (15, 16) . Translation of this mRNA would result in a substantial deletion in the polypeptide before the active-site serine. Furthermore, exons 13 and 15 belong to different splice junction types (9) , and this difference would cause a shift in the reading frame of the mRNA. In addition, proteins with abnormal sequences derived from aberrantly spliced transcripts would probably be unstable and rapidly degraded. (iv) The abnormally spliced mRNAs may not be transported into the cytoplasm and may never be translated (14) . Splice junction abnormalities have also been seen for hemophilia B (17) and Tay-Sachs disease (18) (19) (20) .
The type-I mutation changed the nucleotide sequence of GTAAC to ATAAC at the splice junction boundary and abolished a Mae III restriction site in the gene for factor XI of CL3 ( Fig. 2A) . Thus, this mutation could be identified by directly screening for the absence of this restriction site in a fragment generated by the PCR from total genomic DNA (21) as well as phage genomic DNA ( Fig. 2A) (Fig. 2B, lane 4) . Analysis of the genomic DNA from the remaining five patients by this technique showed that none of these individuals carried the type-I mutation (Fig. 2B, lanes 5-9) . Hence, of the 12 defective factor XI genes examined in this investigation, only 1 (- lanes) and after (+ lanes) cleavage using the cloned phage DNA of CL3 and genomic DNA of the six patients. Lanes: 1, DNA from normal control; 2, DNA from phage clone CL3-6; 3, DNA from phage clone CL3-2; 4, genomic DNA from CL3; 5 and 6, genomic DNA from CL1 and CL2; 7-9, genomic DNA from CL4-CL6. The outer two lanes show DNA standards and size of these bands. changed to a stop codon of TAA (Fig. 1B) . Premature polypeptide termination may result in a truncated and presumably unstable factor XI protein from this allele. It may also lead to other abnormalities, such as factor XI mRNA deficiency, without changing cytoplasmic factor XI mRNA stability, as described for the ,B°-39 thalassemia gene (22) .
A change of G to A at Glu-117 also abolishes a recognition site for Bsm I (GAATGC to TAATGC) (Fig. 3A) . Accordingly, a separate PCR analysis was developed by using a second set of oligonucleotide primers (PCE1 and PCE2, Fig.  3A ). This procedure resulted in 125-and 301-bp fragments from normal DNA (Fig. 3B, lane 1) and a 426-bp fragment from mutant DNA after digestion with Bsm I (Fig. 3B, lane  3) . Furthermore, the type-I and type-II mutations in CL3 were each present in a separate allele (Fig. 3B, lane 2 Fig. LA . This result was confirmed by a DNA sequence analysis of the genomic subclones CL3-2 and CL3-6. These experiments showed that the sequence for codon 117 was normal in clone CL3-2 that carried the type-I mutation. Also, the sequence of the intron N junction was normal in clone CL3-6 that carried the type-II mutation. Although only a single clone of the 5' half of the factor XI gene was analyzed, the two mutations in the 3' half of the gene can account for the deficiency in CL3. Furthermore, an analysis of the parents of CL3 by the PCR-Bsm I assay and the PCR-Mae III assay showed that the type-I mutation was present in the father, whereas the type-II mutation originated from the mother (data not shown). The application of this test to the genomic DNA of the remaining five factor XI-deficient patients indicated that CL1, CL2, CL5, and CL6 also carried the type-II mutation and, in all cases, in the heterozygous state (Fig. 3B, lanes 5, 6, 8 , and 9), whereas it was absent in CL4 (Fig. 3B, lane 7) . The results for CL1 were somewhat surprising because this individual resulted from a consanguineous marriage.
Type-III Mutation (Amino Acid Substitution). Mutations in CL4 were studied by direct PCR amplification and sequence analysis. A third point mutation (type III) was identifed in CL4. This mutation was located in exon 9, where TTC coding for Phe-283 was changed to CTC coding for leucine (Fig. 4) . The type-III mutation was not an artifact due to misincorporation of dNTP by the Thermus aquaticus (Taq) polymerase because it was seen in all the amplified clones from exon 9 and was also present in four other patients, as described below. The single base change of T to C generated a new Sau3AI site (GATC) at the mutation site, making it possible to study the 711-bp PCR product that includes exons 8-10 by Sau3AI digestion (Fig. 5A) . Normal DNA gives bands of 581 and 130 bp in length (Fig. SB, lane 1) , whereas in CL4 the 581-bp band was converted to fragments of 330 and 251 bp, and the 130-bp fragment remained unchanged (Fig. SB, lane  2) . Furthermore, CL4 was homozygous for this mutation. PCR amplification and Sau3AI cleavage analysis of the genomic DNA from the remaining five factor XI-deficient patients showed that the type III mutation was also present in one of the alleles of CL1, CL2, CL5, and CL6 (Fig. SB,  lanes 4, 5, 7, and 8) .
Fifty-three apparently normal, unrelated Ashkenazi Jews from Cuyahoga County in northern Ohio were also analyzed to test whether the type-III mutation resulted from polymorphism. The selection of individuals with normal factor XI levels was difficult, however, due to the high frequency of heterozygotes in this population and the absence of bleeding (24) . It is also possible, however, that the type-III mutation is linked to another mutation yet to be identified. In either case, the conversion of Phe-283 to leucine in five of the six patients indicates a factor XI abnormality. Site (7) . Mutations that cause factor XI deficiency probably occurred after the establishment of the three major Jewish communities (Ashkenazi, Oriental, and Sephardic). Unlike Tay-Sachs disease and Gaucher disease, factor XI deficiency has not been traced to a specific geographic origin (7) . The identification of more than one type ofgenetic defect in the present study is inconsistent with the hypothesis that a single mutation for factor XI deficiency in Ashkenazi Jews has spread in this population by a typical founder effect, as discussed by Diamond and Rotter (27, 28) .
It is worthwhile to mention that three lipid-storage diseases caused by defects of different lysosomal hydrolases are also found in high frequency in the subpopulation of Ashkenazi Jews of eastern Europe descent, a finding that supports the role of a founder effect in these disorders (29) . Recent DNA studies of individuals with Tay-Sachs disease (18-20, 30, 31) and Gaucher disease (32) , however, showed the existence of at least three different mutations being responsible for each of these disorders. For infantile Tay-Sachs disease in the Ashkenazi Jews, the splice junction mutation accounted for -30% of the patients and a 4-bp insertion accounted for the remaining 70%. With factor XI deficiency, type-II mutation accounted for 42% of the abnormal alleles, and type-III mutation accounted for 50% of the abnormal alleles in the present six patients. Some selective advantage (28) probably exists in maintaining the high frequency of these mutations in this population. On the other hand, the importance of genetic drift is recognized in the various "Ashkenazi diseases" because there are geographical aggregations of ancestral origins for many of these diseases (29) .
